NLRP3 and diabetes mellitus: Blockade of NLRP3 inflammasome activation by ROS inhibitors significantly down-regulated ZO-1/ZO-2 and alleviated endothelial hyperpermeability in DM, suggesting a loss of function of the NLRP3 inflammasome (92).